Related Experiment Video
Updated: May 21, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Histological and molecular evaluation of patient-derived colorectal cancer explants
Joshua M Uronis1, Takuya Osada, Shannon McCall
1Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, United States of America.
Abstract:
Mouse models have been developed to investigate colorectal cancer etiology and evaluate new anti-cancer therapies. While genetically engineered and carcinogen-induced mouse models have provided important information with regard to the mechanisms underlying the oncogenic process, tumor xenograft models remain the standard for the evaluation of new chemotherapy and targeted drug treatments for clinical use. However, it remains unclear to what extent explanted colorectal tumor tissues retain inherent pathological features over time. In this study, we have generated a panel of 27 patient-derived colorectal cancer explants (PDCCEs) by direct transplantation of human colorectal cancer tissues into NOD-SCID mice. Using this panel, we performed a comparison of histology, gene expression and mutation status between PDCCEs and the original human tissues from which they were derived. Our findings demonstrate that PDCCEs maintain key histological features, basic gene expression patterns and KRAS/BRAF mutation status through multiple passages. Altogether, these findings suggest that PDCCEs maintain similarity to the patient tumor from which they are derived and may have the potential to serve as a reliable preclinical model that can be incorporated into future strategies to optimize individual therapy for patients with colorectal cancer.
Insights
Patient-derived colorectal cancer explants (PDCCEs) in mice retain key tumor features. This suggests PDCCEs are a reliable preclinical model for developing personalized colorectal cancer therapies.
Area of Science:
- Oncology
- Translational Research
- Preclinical Modeling
Background:
- Mouse models are crucial for colorectal cancer research.
- Tumor xenografts are standard for evaluating new cancer treatments.
- The fidelity of explanted tumor tissues over time is not well understood.
Purpose of the Study:
- To assess the reliability of patient-derived colorectal cancer explants (PDCCEs) as preclinical models.
- To compare PDCCEs with original patient tumors for key pathological features.
Main Methods:
- Generated 27 patient-derived colorectal cancer explants (PDCCEs) by transplanting human tumors into NOD-SCID mice.
- Compared histology, gene expression, and mutation status between PDCCEs and original patient tissues.
- Evaluated feature retention across multiple passages.
Main Results:
- PDCCEs successfully maintained key histological features.
- Basic gene expression patterns were preserved in PDCCEs.
- KRAS/BRAF mutation status remained consistent through multiple passages.
Conclusions:
- Patient-derived colorectal cancer explants (PDCCEs) closely resemble the original patient tumors.
- PDCCEs show potential as a reliable preclinical model for colorectal cancer.
- PDCCEs may aid in optimizing individualized colorectal cancer therapies.
More Related Videos
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
09:16High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
Published on: June 14, 2018